target directory

glucagon like peptide 1 receptor glp 1r clinical trial intelligence

Trials are included when the normalized target field matches this target directory. Full protocol, result, eligibility and IP analysis is available inside the premium workspace.

Validated reports

Directory type

target

Association rule

normalized field

NCT05659537

Source recordAI-normalized

A 24-week Multicenter, Open-label, Single-arm Study to Evaluate Safety in Patients With Type 2 Diabetes Mellitus in India Treated With Dulaglutide

Eli Lilly's dulaglutide, a GLP-1 receptor agonist, is being evaluated for safety in a diverse population of patients with Type 2 Diabetes Mellitus (T2DM) in India. Given the increasing prevalence of diabetes in India, this study addresses a significant market need. The results could reinforce dulaglutide's position in the competitive landscape against other GLP-1 receptor agonists and oral antihyperglycemic agents. Successful outcomes may enhance market penetration and support further regulatory approvals in the region. Additionally, the study's completion and subsequent data publication will be critical for Eli Lilly's ongoing commercial strategy and investor confidence.

AI analysis

Indication: Diabetes Mellitus, Type 2

Modality: small molecule

Target: Glucagon-like peptide-1 receptor (GLP-1R)

Sponsor: Eli Lilly and Company

Source URL: ClinicalTrials.gov

Source updated: Detailed source ingestion pending

Ingested: Aug 01, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by target_normalized: Glucagon-like peptide-1 receptor (GLP-1R)

View original source fields

Condition raw: Diabetes Mellitus, Type 2

Condition normalized: Diabetes Mellitus, Type 2

Modality raw: small molecule

Modality normalized: small molecule

Target raw: Glucagon-like peptide-1 receptor (GLP-1R)

Target normalized: Glucagon-like peptide-1 receptor (GLP-1R)

Open report

NCT00799435

Source recordAI-normalized

Treatment With Glucagon-Like Peptide-1 Receptor, Exenatide, in Patients With Diabetes and Heart Failure With Normal Left Ventricular Ejection Fraction

The study aimed to evaluate the effects of exenatide, a GLP-1 receptor agonist, on heart failure in patients with type 2 diabetes. Despite the potential market for diabetes medications that also address cardiovascular complications, the trial was terminated due to inadequate recruitment. This indicates challenges in patient enrollment for studies targeting specific comorbidities, which may affect future clinical development strategies. The competitive landscape includes other GLP-1 receptor agonists and heart failure treatments, necessitating a focus on differentiated clinical benefits to capture market share.

AI analysis

Indication: Diabetes Mellitus, Type 2

Modality: small molecule

Target: Glucagon-Like Peptide-1 Receptor (GLP-1R)

Sponsor: Baylor College of Medicine

Source URL: ClinicalTrials.gov

Source updated: Detailed source ingestion pending

Ingested: Jul 15, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by target_normalized: Glucagon-Like Peptide-1 Receptor (GLP-1R)

View original source fields

NCT02602600

Source recordAI-normalized

Effect of Glucagon-like Peptide-1 Stimulation on Coronary Microvascular Dysfunction in Women With Angina Pectoris and no Obstructive Stenosis of Major Coronary Vessels

The clinical trial investigates the efficacy of Liraglutide, a GLP-1 receptor agonist, in treating coronary microvascular dysfunction in women with angina pectoris but no obstructive coronary artery disease. Given the increasing prevalence of cardiovascular diseases and the lack of effective treatments for microvascular angina, successful outcomes could position Liraglutide as a novel therapeutic option in this niche market. The trial's completion may enhance the commercial viability of Liraglutide beyond its current indications for diabetes and obesity, potentially expanding its market share. However, competition from other GLP-1 receptor agonists and cardiovascular therapies must be considered in market positioning and strategy.

AI analysis

Indication: Microvascular Angina

Modality: small molecule

Target: Glucagon-like peptide-1 receptor (GLP-1R)

Sponsor: Eva Prescott

Source URL: ClinicalTrials.gov

Source updated: Detailed source ingestion pending

Ingested: Jul 11, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by target_normalized: Glucagon-like peptide-1 receptor (GLP-1R)